{"url_path":"/sec/cik-0001657677/8-k/2026-06-11/item-3-02","section_key":"item-3-02","section_title":"Item 3.02 Unregistered Sales of Equity Securities.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1657677/0001193125-26-267550-index.html","accession_number":"0001193125-26-267550","cik":"0001657677","ticker":null,"issuer_name":"Parabilis Medicines, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1657677/0001193125-26-267550-index.html","primary_entity_key":"0001657677","primary_entity_name":"Parabilis Medicines, Inc."},"word_count":170,"has_tables":true,"body_markdown":"Item 3.02 Unregistered Sales of Equity Securities.\n\nTo the extent required by Item 3.02 of Form 8-K, the information regarding the Shares sold in the Private Placement set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference in this Item 3.02. The Shares issued and sold in the Private Placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws, and were issued and sold pursuant to Section 4(a)(2) of the Securities Act. Regeneron has represented that it is an “institutional accredited investor” within the meaning of Rule 501 of Regulation D under the Securities Act, and is acquiring the Shares for investment purposes only and not with a view to any public distribution or with any intention of selling, distributing or otherwise disposing of the Shares in a manner that would violate the registration requirements of the Securities Act. The Shares were offered without any general solicitation by the Company or its representatives."}